| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group PY Wen, DR Macdonald, DA Reardon, TF Cloughesy, AG Sorensen, ... Journal of clinical oncology 28 (11), 1963-1972, 2010 | 3580 | 2010 |
| Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ... New England Journal of Medicine 370 (8), 709-722, 2014 | 2369 | 2014 |
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma D Sturm, H Witt, V Hovestadt, DA Khuong-Quang, DTW Jones, ... Cancer cell 22 (4), 425-437, 2012 | 1777 | 2012 |
| DNA methylation-based classification of central nervous system tumours D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ... Nature 555 (7697), 469-474, 2018 | 1699 | 2018 |
| An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor CA Opitz, UM Litzenburger, F Sahm, M Ott, I Tritschler, S Trump, ... Nature 478 (7368), 197-203, 2011 | 1641 | 2011 |
| Identifying the best machine learning algorithms for brain tumor segmentation, progression assessment, and overall survival prediction in the BRATS challenge S Bakas, M Reyes, A Jakab, S Bauer, M Rempfler, A Crimi, RT Shinohara, ... arXiv preprint arXiv:1811.02629, 2018 | 1263 | 2018 |
| Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas C Hartmann, J Meyer, J Balss, D Capper, W Mueller, A Christians, ... Acta neuropathologica 118, 469-474, 2009 | 1197 | 2009 |
| Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial W Wick, M Platten, C Meisner, J Felsberg, G Tabatabai, M Simon, ... The lancet oncology 13 (7), 707-715, 2012 | 1130 | 2012 |
| Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo S Fulda, W Wick, M Weller, KM Debatin Nature medicine 8 (8), 808-815, 2002 | 985 | 2002 |
| Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity ME Hegi, L Liu, JG Herman, R Stupp, W Wick, M Weller, MP Mehta, ... Journal of clinical oncology 26 (25), 4189-4199, 2008 | 947 | 2008 |
| NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide W Wick, C Hartmann, C Engel, M Stoffels, J Felsberg, F Stockhammer, ... Journal of clinical oncology 27 (35), 5874, 2009 | 928 | 2009 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 915 | 2014 |
| Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the … C Hartmann, B Hentschel, W Wick, D Capper, J Felsberg, M Simon, ... Acta neuropathologica 120, 707-718, 2010 | 903 | 2010 |
| European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas M Weller, M Van Den Bent, JC Tonn, R Stupp, M Preusser, ... The lancet oncology 18 (6), e315-e329, 2017 | 874 | 2017 |
| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 797 | 2017 |
| MGMT promoter methylation in malignant gliomas: ready for personalized medicine? M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ... Nature Reviews Neurology 6 (1), 39-51, 2010 | 780 | 2010 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 768 | 2017 |
| Stem cell–related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma A Murat, E Migliavacca, T Gorlia, WL Lambiv, T Shay, MF Hamou, ... Journal of clinical oncology 26 (18), 3015-3024, 2008 | 765 | 2008 |
| Brain tumour cells interconnect to a functional and resistant network M Osswald, E Jung, F Sahm, G Solecki, V Venkataramani, J Blaes, S Weil, ... Nature 528 (7580), 93-98, 2015 | 752 | 2015 |
| Lomustine and bevacizumab in progressive glioblastoma W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ... New England Journal of Medicine 377 (20), 1954-1963, 2017 | 711 | 2017 |
Olivier ChinotProfesseur d'Oncologie, Aix-Marseille UniversitéVerified email at ap-hm.fr
